Enalapril, hydrochlorothiazide, and combination therapy in patients with moderate hypertension

W. H. Frishman, Jeffrey Goldberger, D. Sherman

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Using a placebo baseline, positive controlled, double-blind, randomized titration to effect our study protocol, we assessed the antihypertensive actions of enalapril, hydrochlorothiazide, and their combination in 37 patients with moderatel essential hypertension. Patients were maintained on their regular diets and received a placebo for 4 weeks. Patients with moderate systemic hypertension were randomized to receive enalapril monotherapy at a dose of 10 mg twice daily (n = 16), hydrochlorothiazide monotherapy at a dose of 25 mg twice daily (n = 15), or combination therapy consisting of 10 mg enalapril and 25 mg hydrochlorothiazide twice daily (n = 6). Therapy could be titrated to twice the starting dose. All treatment regimens reduced blood pressure, but only one patient had blood pressure normalized (diastolic blood pressure ≤ 90 mmHg) with enalapril {7%}, two patients with hydrochlorothazide {15%}, and 80% of patients with combination therapy. The patients who had not achieved normal blood pressure received combination treatment, and after 8 additional weeks, more than 70% showed normal blood pressure. After one year of combination therapy, 92% of the patients continue to have normal blood pressure. Both the monotherapy and combination regimens were very well tolerated in this study. In conclusion, enalapril, hydrochlorothiazide, and their combination are effective in reducing blood pressure in patients with moderate hypertension. However, monotherapy is successful in normalizing blood pressure only in a small percentage of patients. Combination therapy achieved normalization of blood pressure in almost all patients, suggesting that most patients on regular diets with moderate hypertension may require a diuretic-ACE inhibitor combination rather than monotherapy to achieve effective blood pressure control.

Original languageEnglish (US)
Pages (from-to)520-527
Number of pages8
JournalJournal of clinical hypertension
Volume3
Issue number4
StatePublished - Dec 1 1987
Externally publishedYes

Fingerprint

Enalapril
Hydrochlorothiazide
Hypertension
Blood Pressure
Therapeutics
Placebos
Diet
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Antihypertensive Agents

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Enalapril, hydrochlorothiazide, and combination therapy in patients with moderate hypertension. / Frishman, W. H.; Goldberger, Jeffrey; Sherman, D.

In: Journal of clinical hypertension, Vol. 3, No. 4, 01.12.1987, p. 520-527.

Research output: Contribution to journalArticle

@article{9cc1792cfa874a8783972f1e0bb78291,
title = "Enalapril, hydrochlorothiazide, and combination therapy in patients with moderate hypertension",
abstract = "Using a placebo baseline, positive controlled, double-blind, randomized titration to effect our study protocol, we assessed the antihypertensive actions of enalapril, hydrochlorothiazide, and their combination in 37 patients with moderatel essential hypertension. Patients were maintained on their regular diets and received a placebo for 4 weeks. Patients with moderate systemic hypertension were randomized to receive enalapril monotherapy at a dose of 10 mg twice daily (n = 16), hydrochlorothiazide monotherapy at a dose of 25 mg twice daily (n = 15), or combination therapy consisting of 10 mg enalapril and 25 mg hydrochlorothiazide twice daily (n = 6). Therapy could be titrated to twice the starting dose. All treatment regimens reduced blood pressure, but only one patient had blood pressure normalized (diastolic blood pressure ≤ 90 mmHg) with enalapril {7{\%}}, two patients with hydrochlorothazide {15{\%}}, and 80{\%} of patients with combination therapy. The patients who had not achieved normal blood pressure received combination treatment, and after 8 additional weeks, more than 70{\%} showed normal blood pressure. After one year of combination therapy, 92{\%} of the patients continue to have normal blood pressure. Both the monotherapy and combination regimens were very well tolerated in this study. In conclusion, enalapril, hydrochlorothiazide, and their combination are effective in reducing blood pressure in patients with moderate hypertension. However, monotherapy is successful in normalizing blood pressure only in a small percentage of patients. Combination therapy achieved normalization of blood pressure in almost all patients, suggesting that most patients on regular diets with moderate hypertension may require a diuretic-ACE inhibitor combination rather than monotherapy to achieve effective blood pressure control.",
author = "Frishman, {W. H.} and Jeffrey Goldberger and D. Sherman",
year = "1987",
month = "12",
day = "1",
language = "English (US)",
volume = "3",
pages = "520--527",
journal = "Journal of clinical hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Enalapril, hydrochlorothiazide, and combination therapy in patients with moderate hypertension

AU - Frishman, W. H.

AU - Goldberger, Jeffrey

AU - Sherman, D.

PY - 1987/12/1

Y1 - 1987/12/1

N2 - Using a placebo baseline, positive controlled, double-blind, randomized titration to effect our study protocol, we assessed the antihypertensive actions of enalapril, hydrochlorothiazide, and their combination in 37 patients with moderatel essential hypertension. Patients were maintained on their regular diets and received a placebo for 4 weeks. Patients with moderate systemic hypertension were randomized to receive enalapril monotherapy at a dose of 10 mg twice daily (n = 16), hydrochlorothiazide monotherapy at a dose of 25 mg twice daily (n = 15), or combination therapy consisting of 10 mg enalapril and 25 mg hydrochlorothiazide twice daily (n = 6). Therapy could be titrated to twice the starting dose. All treatment regimens reduced blood pressure, but only one patient had blood pressure normalized (diastolic blood pressure ≤ 90 mmHg) with enalapril {7%}, two patients with hydrochlorothazide {15%}, and 80% of patients with combination therapy. The patients who had not achieved normal blood pressure received combination treatment, and after 8 additional weeks, more than 70% showed normal blood pressure. After one year of combination therapy, 92% of the patients continue to have normal blood pressure. Both the monotherapy and combination regimens were very well tolerated in this study. In conclusion, enalapril, hydrochlorothiazide, and their combination are effective in reducing blood pressure in patients with moderate hypertension. However, monotherapy is successful in normalizing blood pressure only in a small percentage of patients. Combination therapy achieved normalization of blood pressure in almost all patients, suggesting that most patients on regular diets with moderate hypertension may require a diuretic-ACE inhibitor combination rather than monotherapy to achieve effective blood pressure control.

AB - Using a placebo baseline, positive controlled, double-blind, randomized titration to effect our study protocol, we assessed the antihypertensive actions of enalapril, hydrochlorothiazide, and their combination in 37 patients with moderatel essential hypertension. Patients were maintained on their regular diets and received a placebo for 4 weeks. Patients with moderate systemic hypertension were randomized to receive enalapril monotherapy at a dose of 10 mg twice daily (n = 16), hydrochlorothiazide monotherapy at a dose of 25 mg twice daily (n = 15), or combination therapy consisting of 10 mg enalapril and 25 mg hydrochlorothiazide twice daily (n = 6). Therapy could be titrated to twice the starting dose. All treatment regimens reduced blood pressure, but only one patient had blood pressure normalized (diastolic blood pressure ≤ 90 mmHg) with enalapril {7%}, two patients with hydrochlorothazide {15%}, and 80% of patients with combination therapy. The patients who had not achieved normal blood pressure received combination treatment, and after 8 additional weeks, more than 70% showed normal blood pressure. After one year of combination therapy, 92% of the patients continue to have normal blood pressure. Both the monotherapy and combination regimens were very well tolerated in this study. In conclusion, enalapril, hydrochlorothiazide, and their combination are effective in reducing blood pressure in patients with moderate hypertension. However, monotherapy is successful in normalizing blood pressure only in a small percentage of patients. Combination therapy achieved normalization of blood pressure in almost all patients, suggesting that most patients on regular diets with moderate hypertension may require a diuretic-ACE inhibitor combination rather than monotherapy to achieve effective blood pressure control.

UR - http://www.scopus.com/inward/record.url?scp=0023623278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023623278&partnerID=8YFLogxK

M3 - Article

C2 - 2839628

AN - SCOPUS:0023623278

VL - 3

SP - 520

EP - 527

JO - Journal of clinical hypertension

JF - Journal of clinical hypertension

SN - 0895-7061

IS - 4

ER -